The failing heart

Nature

Volumn 415, Issue 6868, 2002, Pages 227-233

  Towbin, J A ^a   Bowles, N E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; GENETIC ENGINEERING; MEDICAL PROBLEMS; MUSCLE;

MOLECULAR MECHANISMS;

BIOLOGICAL ORGANS;

DISEASE;

CARDIOMYOPATHY; DIAGNOSTIC TEST; GENETICS; HEART FAILURE; HUMAN; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PUMP; REVIEW; UNITED STATES;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; DISEASE MODELS, ANIMAL; FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0037050022     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/415227a     Document Type: Review

References (75)

1. Economic impact of heart failure in the United States: Time for a different approach
2. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies
3. Restrictive cardiomyopathy
4. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study
5. Right ventricular cardiomyopathy and sudden death in young people
6. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia
7. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy
8. The challenge of cardiomyopathy
9. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies
10. Idiopathic cardiomyopathy in the United States
11. Frequency and phenotypes of familial dilated cardiomyopathy
12. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32
13. Familial dilated cardiomyopathy locus maps to chromosome 2q31
14. Desmin mutations responsible for idiopathic dilated cardiomyopathy
15. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β-sarcoglycan mutations
16. Mutations in the human δ-sarcoglycan gene in familial and sporadic dilated cardiomyopathy
17. Linkage of familial dilated cardiomyopathy to chromosome 9
18. Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23
19. Mutations in sarcomeric protein genes as a cause of dilated cardiomyopathy
20. Mutations that alter the surface change of α-tropomyosin are associated with dilated cardiomyopathy
21. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
22. α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy
23. α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere
24. Desmin-related myopathies in mice and man
25. Sarcoglycans in muscular dystrophy
26. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex
27. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy
28. A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1
29. Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22
30. Mapping a cardiomyopathy locus to chromosome 3p22-p25
31. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23
32. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutant in the α-cardiac myosin heavy chain gene
33. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement
34. X-linked dilated cardiomyopathy
35. X-linked dilated cardiomyopathy (XLCM): Molecular genetic evidence of linkage to the Duchenne muscular dystrophy gene at the Xp21 locus
36. Brief report: Deletion of the dystrophin muscle-specific promoter region associated with X-linked dilated cardiomyopathy
37. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
38. The association of cardiac dystrophin with myofibrils/z-discs regions in cardiac muscle suggests a novel role in the contractile apparatus
39. Distinct patterns of dystrophin organization in myocyte sarcolemma and transverge tubules of normal and diseased human myocardium
40. Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage
41. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy
42. Dystrophies and heart disease
43. Animal models for muscular dystrophy: Valuable tools for the development of therapies
44. Cardiomyopathy in animal models of muscular dystrophy
45. Dystrophin protects the sarcolemma from stresses developed during muscle contraction
46. The role of cytoskeletal proteins in cardiomyopathies
47. The "final common pathway" hypothesis and inherited cardiovascular disease: The role of cytoskeletal proteins in dilated cardiomyopathy
48. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes
49. X-linked dilated cardiomyopathy with neutropenia, growth retardation, and 3-methylglutaconic aciduria
50. A novel X-linked gene, G4.5 is responsible for Barth syndrome
51. The X-linked gene G 4.5 is responsible for different infantile dilated cardiomyopathies
52. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome
53. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure
54. Enteroviral protease 2A cleaves dystrophin's evidence of cytoskeletal disruption in an acquired cardiomyopathy
55. Hypertrophic cardiomyopathy
56. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1
57. Molecular genetics of hypertrophic cardiomyopathy
58. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2
59. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
60. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy
61. Mutations in the skeletal muscle α-actin gene in patients with actin myopathy and nemaline myopathy
62. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome
63. Manipulating the contractile apparatus: Genetically defined animal models of cardiovascular disease
64. Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the α-cardiac myosin heavy chain gene
65. A transgenic rabbit model for human hypertrophic cardiomyopathy
66. Familial hypertrophic cardiomyopathy in Main Coon cats. An animal model of human disease
67. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12
68. Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies
69. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
70. Congestive heart failure: Fifty years of progress
71. Mechanical circulatory support for advanced heart failure. Effect of patient selection or outcome
72. Evidence for reversible dystrophin abnormalities in patients with non-familial dilated cardiomyopathies: Observations in patients treated with long-term mechanical support
73. Prevention of cardiomyopathy in mouse models lacking smooth muscle sarcoglycan-sarcospan complex
74. Sarcoglycan, the heart, and skeletal muscles: New treatment, old drug?